Evidence map›Paper›PMID 36910690›Full record

ArticleOpen forum infectious diseases2023

Malaria Control by Mass Drug Administration With Artemisinin Plus Piperaquine on Grande Comore Island, Union of Comoros.

Changsheng Deng, Wanting Wu, Yueming Yuan, Guoming Li, Hongying Zhang, Shaoqin Zheng, Mingqiang Li, Ruixiang Tan, Yuxin Wang, Julie Nadia and 15 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Changsheng DengArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Wanting WuArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Yueming YuanArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Guoming LiArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.ORCID https://orcid.org/0000-0003-1748-8084
Hongying ZhangArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Shaoqin ZhengArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Mingqiang LiArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.ORCID https://orcid.org/0000-0002-7216-5942
Ruixiang TanArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Yuxin WangArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Julie NadiaArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Danhong FengScience and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Di LiScience and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Zhibing WuFirst Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Qin XuArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Changqing LiArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Zhenhua WangArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Yuan LiangScience and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
Johannes S P DoehlLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-9374-6706
Xinzhuan SuLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-3246-3248
Affane BacarNational Malaria Center of The Union of Comoros, Moroni, The Union of Comoros.
Kamal Said AbdallahNational Malaria Center of The Union of Comoros, Moroni, The Union of Comoros.ORCID https://orcid.org/0000-0001-9074-094X
Hafidhou MohamedNational Malaria Center of The Union of Comoros, Moroni, The Union of Comoros.
Ahamada Msa MlivaNational Malaria Center of The Union of Comoros, Moroni, The Union of Comoros.
Thomas E WellemsLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-3899-8454
Jianping SongArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.

Funding

Malaria Drug Resistance and Disease VirulenceZIAAI000483 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WELLEMS, THOMAS E · 2009 to 2025
$24.5M
Malaria Parasite Sexual Development, Drug Resistance, and EvolutionZIAAI000892 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SU, XINZHUAN · 2009 to 2025
$23.3M
6 · The paper itself

Abstract

Background: Mass drug administration (MDA) is a powerful tool for malaria control, but the medicines to use, dosing, number of rounds, and potential selection of drug resistance remain open questions. Methods: Two monthly rounds of artemisinin-piperaquine (AP), each comprising 2 daily doses, were administered across the 7 districts of Grande Comore Island. In 3 districts, low-dose primaquine (PMQ Results: Average population coverages of 80%-82% were achieved with AP in 4 districts (registered population 258 986) and AP + PMQ Conclusions: MDA with 2 monthly rounds of 2 daily doses of AP was highly effective on Grande Comore Island. The feasibility and lower expense of this 2-month versus 3-month regimen of AP may offer advantages for MDA programs in appropriate settings.

Indexed as

artemisinin-based combination therapychloroquine resistance transporter (PfCRT)pfK13 kelch-propeller mutationspiperaquine resistancePlasmodium falciparum malaria

Identifiers

PMID36910690
PMCPMC10003749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.